Literature DB >> 34172937

Defining comprehensive models of care for NAFLD.

Manuel Romero-Gómez1, Jörn M Schattenberg2, Jeffrey V Lazarus3,4, Quentin M Anstee5,6, Hannes Hagström7, Kenneth Cusi8, Helena Cortez-Pinto9, Henry E Mark10, Michael Roden11,12,13, Emmanuel A Tsochatzis14,15, Vincent Wai-Sun Wong16, Zobair M Younossi17, Shira Zelber-Sagi18,19.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease globally. Despite the increased demand placed on health-care systems, little attention has been given to the design and implementation of efficient and effective models of care for patients with NAFLD. In many health-care settings, no formal pathways exist and, where pathways are in place, they are often not standardized according to good practices. We systematically searched the peer-reviewed literature with the aim of identifying published examples of comprehensive models of care that answered four key questions: what services are provided? Where are they provided? Who is offering them? How are they coordinated and integrated within health-care systems? We identified seven models of care and synthesized the findings into eight recommendations nested within the 'what, where, who and how' of care models. These recommendations, aimed at policy-makers and practitioners designing and implementing models of care, can help to address the increasing need for the provision of good practice care for patients with NAFLD.

Entities:  

Year:  2021        PMID: 34172937     DOI: 10.1038/s41575-021-00477-7

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  87 in total

1.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

2.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Authors:  Chris Estes; Quentin M Anstee; Maria Teresa Arias-Loste; Heike Bantel; Stefano Bellentani; Joan Caballeria; Massimo Colombo; Antonio Craxi; Javier Crespo; Christopher P Day; Yuichiro Eguchi; Andreas Geier; Loreta A Kondili; Daniela C Kroy; Jeffrey V Lazarus; Rohit Loomba; Michael P Manns; Giulio Marchesini; Atsushi Nakajima; Francesco Negro; Salvatore Petta; Vlad Ratziu; Manuel Romero-Gomez; Arun Sanyal; Jörn M Schattenberg; Frank Tacke; Junko Tanaka; Christian Trautwein; Lai Wei; Stefan Zeuzem; Homie Razavi
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

Review 3.  NAFLD: a multisystem disease.

Authors:  Christopher D Byrne; Giovanni Targher
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 4.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Authors:  Leon A Adams; Quentin M Anstee; Herbert Tilg; Giovanni Targher
Journal:  Gut       Date:  2017-03-17       Impact factor: 23.059

5.  Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study.

Authors:  Sung Keun Park; Mi Hae Seo; Ho Cheol Shin; Jae-Hong Ryoo
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

Review 6.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

Review 7.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

8.  Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.

Authors:  Svanhildur Haflidadottir; Jon G Jonasson; Helga Norland; Sylvia O Einarsdottir; David E Kleiner; Sigrun H Lund; Einar S Björnsson
Journal:  BMC Gastroenterol       Date:  2014-09-27       Impact factor: 3.067

Review 9.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.

Authors:  Chris Estes; Homie Razavi; Rohit Loomba; Zobair Younossi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-12-01       Impact factor: 17.425

Review 10.  Natural History of NAFLD/NASH.

Authors:  Mattias Ekstedt; Patrik Nasr; Stergios Kechagias
Journal:  Curr Hepatol Rep       Date:  2017-11-13
View more
  11 in total

1.  Metabolic abnormalities play a crucial role in non-obese people suffering from non-alcoholic fatty liver disease (NAFLD).

Authors:  Qing Ye; Takanori Ito; Linda Henry; Mindie H Nguyen
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

Review 2.  Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease.

Authors:  Xin-Lei Zhang; Ting-Yao Wang; Giovanni Targher; Christopher D Byrne; Ming-Hua Zheng
Journal:  Diabetes Metab J       Date:  2022-05-25       Impact factor: 5.893

3.  Clinicians' Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study.

Authors:  Yasaman Vali; Roel Eijk; Timothy Hicks; William S Jones; Jana Suklan; Adriaan G Holleboom; Vlad Ratziu; Miranda W Langendam; Quentin M Anstee; Patrick M M Bossuyt
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

4.  CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.

Authors:  Lucija Virović Jukić; Ivica Grgurević; Ivana Mikolašević; Tajana Filipec Kanižaj; Sandra Milić; Anna Mrzljak; Marina Premužić; Irena Hrstić; Ivana Knežević-Štromar; Neven Ljubičić; Rajko Ostojić; Sanja Stojsavljević Shapeski; Vjekoslava Amerl-Šakić; Nina Bašić Marković; Marko Rađa; Dragan Soldo; Nikola Sobočan; Miloš Lalovac; Željko Puljiz; Kristian Podrug; Dinko Ladić
Journal:  Acta Clin Croat       Date:  2021-12       Impact factor: 0.932

5.  Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany.

Authors:  Karl J Lackner; Jörn M Schattenberg; Yvonne Huber; Andreas Schulz; Irene Schmidtmann; Manfred Beutel; Norbert Pfeiffer; Thomas Münzel; Peter R Galle; Philipp S Wild
Journal:  Hepatol Commun       Date:  2022-02-05

6.  Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease.

Authors:  Mirko Zoncapè; Antonio Liguori; Emmanuel A Tsochatzis
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

7.  Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes.

Authors:  Patrizia Carrieri; Abbas Mourad; Fabienne Marcellin; Aldo Trylesinski; José Luis Calleja; Camelia Protopopescu; Jeffrey V Lazarus
Journal:  Liver Int       Date:  2022-03-07       Impact factor: 8.754

8.  High Meat Consumption Is Prospectively Associated with the Risk of Non-Alcoholic Fatty Liver Disease and Presumed Significant Fibrosis.

Authors:  Dana Ivancovsky-Wajcman; Naomi Fliss-Isakov; Laura Sol Grinshpan; Federico Salomone; Jeffrey V Lazarus; Muriel Webb; Oren Shibolet; Revital Kariv; Shira Zelber-Sagi
Journal:  Nutrients       Date:  2022-08-27       Impact factor: 6.706

Review 9.  Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease.

Authors:  Anne-Marieke van Dijk; Jörn M Schattenberg; Adriaan G Holleboom; Maarten E Tushuizen
Journal:  United European Gastroenterol J       Date:  2021-10-05       Impact factor: 4.623

10.  An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care.

Authors:  Lucy Gracen; Kelly L Hayward; Melanie Aikebuse; Suzanne Williams; Anthony Russell; James O'Beirne; Elizabeth E Powell; Patricia C Valery
Journal:  Diabet Med       Date:  2022-02-07       Impact factor: 4.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.